BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study

作者：Yuxiang Ma, Yan Huang, Yuanyuan Zhao, Shen Zhao, Jinhui Xue, Yunpeng Yang, Wen‐Feng Fang, Ye Guo, Yaqian Han, Kunyu Yang, Yongsheng Li, Jun Yang, Zhenming Fu, Gang Chen, Likun Chen, Ningning Zhou, Ting Zhou, Yaxiong Zhang, Huaqiang Zhou, Qianwen Liu, Yi Zhu, Hai Zhu, Sa Xiao, Li Zhang, Hongyun Zhao · 发表于：The Lancet Oncology · 年份：2024 · DOI：10.1016/s1470-2045(24)00159-1 · 被引用次数：142 · 研究领域：HER2/EGFR in Cancer Research、Monoclonal and Polyclonal Antibodies Research、Colorectal Cancer Treatments and Studies